Myeloperoxidase and eosinophil cationic protein in serum and sputum during antibiotic treatment in cystic fibrosis patients with Pseudomonas aeruginosa infection

• Published in: Mediators of Inflammation Vol. 1995; no. 4; pp. 282 - 288
• Main Authors: Niggemann, B, Stiller, T, Magdorf, K, Wahn, U
• Format: Journal Article
• Language: English
• Published: United States Hindawi Limiteds 1995; Hindawi Publishing Corporation; Hindawi Limited
• Subjects: Cystic fibrosis; Myeloperoxidase; Eosinophil cationic protein; Pseudomonas aerugonisa
• ISSN: 0962-9351; 1466-1861
• DOI: 10.1155/S0962935195000457

IN order to study the time-course of myeloperoxidase (MPO) and eosinophil cationic protein (ECP) as parameters for monitoring inflammation in cystic fibrosis (CF), we investigated ten patients during both a 14-day intravenous antibiotic treatment and a corresponding self control. Modified Shwachman-Kulczycki score improved significantly (p ＜ 0.008), C-reactive protein (CRP) levels decreased significantly (p ＜ 0.05) during antibiotic treatment, while in the control phase there were no significant differences. Lung function parameters did not change significantly during antibiotic treatment or control phase. Serum MPO concentration (p ＜ 0.006) and peripheral blood neutrophil granulocyte counts (p ＜ 0.04) decreased significantly during antibiotic treatment, but not during the control phase. Sentm ECP concentration showed a tendency to decrease during antibiotic treatment, but this failed to reach significance. In general, sputum concentrations of MPO and ECP Were 500- to 1000-fold higher than in serum. However, neither MPO nor ECP in sputum showed a significan variation over time during antibiotic treatment or control phase. From our data we conclude that: (1) measurements of MPO, neutrophils and CRP in peripheral blood do correlate with clinical parameters such as the modified Shwachman-Kulczycki score; (2) neutrophils and MPO seem to reflect inflammatory changes induced by antibiotic treatment; (3) eosinophils may play a role in CF by an enhanced 'releasability' and (4) Sputum measurements of mediators of inflammation cannot be recommended.